OCDMicro + fullBothModerate evidence

One small trial is the entire case for psilocybin and OCD

A review finds one small trial and a trail of case reports going back to the sixties.

2024Published

Narrative reviewStudy type

Review of existing literatureSample

What they did

A researcher reviewed everything published on psychedelics for obsessive-compulsive disorder, covering the proposed mechanisms alongside the clinical evidence.

What they found

The evidence base is one small open-label trial in nine people plus a series of case reports. In that trial, 88.9 percent of participants saw at least a 25 percent symptom improvement and 66.7 percent saw at least a 50 percent reduction.

1trial in the entire literature

9people in it

Worth knowing

This review is the reason OCD keeps appearing in psilocybin coverage, and it exists to point out how thin the evidence is. Everything beyond that single nine-person study is case reports dating back to the 1960s.

Collins. Psychedelics for the Treatment of Obsessive-Compulsive Disorder, Efficacy and Proposed Mechanisms. International Journal of Neuropsychopharmacology, 2024.

Read the source

Keep reading

eating disordersTwenty-one women with anorexia, and symptoms that improved for a year cluster headacheCluster headaches dropped on psilocybin, but not significantly OCDNine people with OCD, and symptoms that dropped within hours

We include the trials that missed their endpoints alongside the ones that hit. A shelf that only holds good news is a marketing page, not a library.

Browse the library

Microdosing 8 Depression 9 Anxiety 6 Addiction 9 Cognition 6 Ageing and injury 3 Brain and plasticity 7 Other conditions 9 Safety 6 All research 63

For education, not medical advice. Every write-up links back to the original source.
Nothing here is a claim that our products treat, cure or prevent any condition. Talk to a doctor before changing anything about your health.